|
|
|
|
Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection
: Vol.2, Issue 14, p. 14ra4 J. Gerardo Garca-Lerma1,*, Mian-er Cong1, James Mitchell1, Ae S. Youngpairoj1, Qi Zheng1, Silvina Masciotra1, Amy Martin1, Zsuzsanna Kuklenyik2, Angela Holder1, Jonathan Lipscomb1, Chou-Pong Pau1, John R. Barr2, Debra L.
|
|
|
Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Maca
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin CROI 2010 Gerardo Garcia-Lerma*1, M-E Cong1, Q Zheng1, A Holder1, A Martin1, C-C Lin1, R Otten1, W Lee2, C-P Pau1, and W Heneine1...
|
|
|
Gilead spent $370,000 lobbying government in 4Q
NEW YORK Biotech drug maker Gilead Sciences Inc.spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form. The spending marks a 54 percent boost from $240,000 spend during the same period in 2008. The company,...
|
|
|
Gilead spent $370,000 lobbying government in 4Q
Biotech drug maker Gilead Sciences Inc.spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form. The spending marks a 54 percent boost from $240,000 spend during the same period in 2008. The company, based in...
|
|
|
Gilead spent $370,000 lobbying government in 4Q
NEW YORK --Biotech drug maker spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form.The spending marks a 54 percent boost from $240,000 spend during the same period in 2008. The company, based in Foster City,...
|
|
|
Gilead Sciences spent $370,000 lobbying federal government during the fourth quarter
NEW YORK Biotech drug maker Gilead Sciences Inc.spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form. The spending marks a 54 percent boost from $240,000 spend during the same period in 2008. The company,...
|
|
|
Gilead Sciences spent $370,000 lobbying federal government during the fourth quarter
NEW YORK Biotech drug maker Gilead Sciences Inc.spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form. The spending marks a 54 percent boost from $240,000 spend during the same period in 2008. The company,...
|
|
|
Gilead spent $370,000 lobbying government in 4Q
NEW YORK (AP) -- Biotech drug maker Gilead Sciences Inc.spent $370,000 lobbying the federal government in the fourth quarter, according to a disclosure form.The spending marks a 54 percent boost from $240,000 spend during the same period in 2008.The company,...
|
|
|
HIV/HBV Coinfected People at High Risk for Disease Progression During Antiretroviral Treatment Interruption
Gregory Dore and colleagues with the SMART INSIGHT study group looked at disease progression among SMART participants coinfected with both HIV and HBV.Briefly, the included more than 5000 mostly ART-experienced participants with a baseline CD4 cell count...
|
|
|
Antivirals: Novel Targets, Technologies, and Dealmaking
The hottest field in antivirals is hepatitis C virus (HCV) drug development; compounds against novel HCV targets such as NS3/4A protease, NS5B polymerase, and NS5A hold the promise of revolutionizing the treatment of this disease.Targeted antivirals have...
|
|
|
Long Case of Gilead Sciences Inc (NASDAQ:GILD)
In the last one year, Gilead Sciences Inc (NASDAQ:GILD) stock has remained an underperformer.Most recently, some of the analysts have recommended a sell on the stock. Should you exit the stock at current levels? I don't think so why is that so? Gilead...
|
|
|
Uptrend in Gilead's Estimates - Analyst Blog
Earnings estimates for Gilead Sciences ( GILD ) are on the rise following the release of strong fourth quarter and full year 2009 results.The companys earnings per share ( EPS ) came in at 90 cents, well above the Zacks Consensus Estimate of 82 cents and the...
|
|
|
Stopping Tenofovir Doesnt Always Reverse Kidney Damage
Kidney damage caused by tenofovir (found in Viread, Truvada and Atripla) may not reverse itself after a year of discontinuing the drug, according to new study results published ahead of print on the website for the Journal of Acquired Immune Deficiency...
|
|
|
Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen
17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco CA February 16-19, 2010 Reported by Jules Levin CROI 2010 Feb 16-19 SF Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in...
|
|
|
ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat
ACTG 5224s, a sub-study of the larger ACTG 5202 trial, looked at 2 types of body composition changes associated with antiretroviral therapy, bone loss and.ACTG 5202 was a randomized Phase 3b clinical trial comparing the effectiveness of commonly used ART...
|
|
|
Tenofovir-associated kidney problems not always reversible
Kidney function does not always return to normal after treatment with tenofovir is discontinued because of renal toxicities, Australian investigators report in an advance online publication in the Journal of Acquired Immune Deficiency Syndromes.An average of...
|
|
|
Cayston Nod a Small Win for Gilead Ahead of New HIV Data
Gilead Sciences Inc.'s ongoing strategy to diversify its pipeline scored a small victory with the approval of inhaled aztreonam lysine drug Cayston, but there's no question the firm's future growth still hinges largely on its next-generation HIV pipeline.
|
|
|
Gilead: A Step in the Right Direction
You are currently following EP Vantage Stop Following You are no longer following EP Vantage About this author: Profile & More Articles Visit: EP Vantage Submit an article to Font Size: Print Email Gilead Sciences (GILD) efforts to expand its repertoire...
|
|
|
Antiretroviral drugs have variable effects on bones and fat, lipoatrophy uncommon with modern regimens
Different antiretroviral regimen components are linked to varying changes in bone mineral density and body fat, according to a sub-study of the U.S.ACTG 5202 trial reported at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) taking...
|
|
|
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppression In Phase II Study
Gilead Sciences, Inc.(Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) for...
|
|
|
Upgrades & Downgrades: Disney is More Beauty than Beast
Stocks rose for a third straight session as a better than expected Philly Fed Index proved Its Always Sunny in Philadelphia.Were also indeed in The Golden Age for Elizabeths. Elizabeth Arden (RDEN) was upgraded on Wednesday, Liz Claiborne (LIZ) today,...
|
|
|
Gileads "Quad"- Eintablettentherapie fr HIV erreicht in Studie der Phase II hohe Rate virologischer Suppression
Zweite Studie der Phase II sttzt GS 9350 (Cobicistat) als verstrkenden Wirkstoff Gilead Sciences, Inc.(Nasdaq: GILD) hat heute die Ergebnisse der Phase II einer klinischen Studie bekannt gegeben. Diese Ergebnisse zeigen, dass die untersuchte Therapie mit...
|
|
|
Gilead Set to Benefit From Newest HIV Drug
/ MRK / BMY / PFE / GSK / ABT / JNJ EP Vantage Send Message You are currently following EP Vantage Stop Following You are no longer following EP Vantage About this author: Profile & More Articles Visit: EP Vantage Submit an article to Font Size: Print Email...
|
|
|
ACTG 5202: No significant difference in time to failure between Kivexa and Truvada in patients with lower vira
Final results from the ACTG 5202 study were presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco on Wednesday morning.Unlike prior results in patients with viral loads higher than 100,000 copies/ml, in which...
|
|
|
Drug stocks edge higher; Genzyme slips
BOSTON (MarketWatch) -- Drug stocks moved higher Wednesday, with shares of Gilead Sciences gaining ground on a positive clinical study for its new HIV combination treatment code-named 'Quad.' S&P 500 (1 YEAR) Market Snapshot: U.S.stocks in focus...
|
